Cargando…

Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release

AIM: To investigate methods for identifying specific cyclophilin D (CypD) inhibitors derived from quinoxaline, thus developing possible lead compounds to inhibit mitochondrial permeability transition (MPT) pore opening. METHODS: Kinetic analysis of the CypD/inhibitor interaction was quantitatively p...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Hong-xia, Wang, Feng, Yu, Kun-qian, Chen, Jing, Bai, Dong-lu, Chen, Kai-xian, Shen, Xu, Jiang, Hua-liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091716/
https://www.ncbi.nlm.nih.gov/pubmed/16174436
http://dx.doi.org/10.1111/j.1745-7254.2005.00189.x
_version_ 1783510051776888832
author Guo, Hong-xia
Wang, Feng
Yu, Kun-qian
Chen, Jing
Bai, Dong-lu
Chen, Kai-xian
Shen, Xu
Jiang, Hua-liang
author_facet Guo, Hong-xia
Wang, Feng
Yu, Kun-qian
Chen, Jing
Bai, Dong-lu
Chen, Kai-xian
Shen, Xu
Jiang, Hua-liang
author_sort Guo, Hong-xia
collection PubMed
description AIM: To investigate methods for identifying specific cyclophilin D (CypD) inhibitors derived from quinoxaline, thus developing possible lead compounds to inhibit mitochondrial permeability transition (MPT) pore opening. METHODS: Kinetic analysis of the CypD/inhibitor interaction was quantitatively performed by using surface plasmon resonance (SPR) and fluorescence titration (FT) techniques. IC(50) values of these inhibitors were determined by PPIase inhibition activity assays. RESULTS: All the equilibrium dissociation constants (K(D)) of the seven compounds binding to CypD were below 10 μmol/L. The IC(50) values were all consistent with the SPR and FT results. Compounds GW2, 5, 6, and 7 had high inhibition activities against Ca(2+)-dependent rat liver mitochondrial swelling and Ca(2+) uptake/release. Compound GW5 had binding selectivity for CypD over CypA. CONCLUSION: The agreement between the measured IC(50) values and the results of SPR and FT suggests that these methods are appropriate and powerful methods for identifying CypD inhibitors. The compounds we screened using these methods (GW1-7) are reasonable CypD inhibitors. Its potent ability to inhibit mitochondrial swelling and the binding selectivity of GW5 indicates that GW5 could potentially be used for inhibiting MPT pore opening.
format Online
Article
Text
id pubmed-7091716
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70917162020-03-24 Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release Guo, Hong-xia Wang, Feng Yu, Kun-qian Chen, Jing Bai, Dong-lu Chen, Kai-xian Shen, Xu Jiang, Hua-liang Acta Pharmacol Sin Article AIM: To investigate methods for identifying specific cyclophilin D (CypD) inhibitors derived from quinoxaline, thus developing possible lead compounds to inhibit mitochondrial permeability transition (MPT) pore opening. METHODS: Kinetic analysis of the CypD/inhibitor interaction was quantitatively performed by using surface plasmon resonance (SPR) and fluorescence titration (FT) techniques. IC(50) values of these inhibitors were determined by PPIase inhibition activity assays. RESULTS: All the equilibrium dissociation constants (K(D)) of the seven compounds binding to CypD were below 10 μmol/L. The IC(50) values were all consistent with the SPR and FT results. Compounds GW2, 5, 6, and 7 had high inhibition activities against Ca(2+)-dependent rat liver mitochondrial swelling and Ca(2+) uptake/release. Compound GW5 had binding selectivity for CypD over CypA. CONCLUSION: The agreement between the measured IC(50) values and the results of SPR and FT suggests that these methods are appropriate and powerful methods for identifying CypD inhibitors. The compounds we screened using these methods (GW1-7) are reasonable CypD inhibitors. Its potent ability to inhibit mitochondrial swelling and the binding selectivity of GW5 indicates that GW5 could potentially be used for inhibiting MPT pore opening. Nature Publishing Group UK 2005-10 /pmc/articles/PMC7091716/ /pubmed/16174436 http://dx.doi.org/10.1111/j.1745-7254.2005.00189.x Text en © CPS and SIMM 2005 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Guo, Hong-xia
Wang, Feng
Yu, Kun-qian
Chen, Jing
Bai, Dong-lu
Chen, Kai-xian
Shen, Xu
Jiang, Hua-liang
Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release
title Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release
title_full Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release
title_fullStr Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release
title_full_unstemmed Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release
title_short Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release
title_sort novel cyclophilin d inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and ca(2+) uptake/release
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091716/
https://www.ncbi.nlm.nih.gov/pubmed/16174436
http://dx.doi.org/10.1111/j.1745-7254.2005.00189.x
work_keys_str_mv AT guohongxia novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease
AT wangfeng novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease
AT yukunqian novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease
AT chenjing novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease
AT baidonglu novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease
AT chenkaixian novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease
AT shenxu novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease
AT jianghualiang novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease